Jiang Caixiao, Han Guangyue, Li Yan, Liu Yanfang, Liu Lanfen, Qi Shunxiang. Drug resistance of influenza A (H1N1) pdm09 virus in Hebei, 2017–2020[J]. Disease Surveillance, 2021, 36(10): 1081-1085. DOI: 10.3784/jbjc.202103240155
Citation: Jiang Caixiao, Han Guangyue, Li Yan, Liu Yanfang, Liu Lanfen, Qi Shunxiang. Drug resistance of influenza A (H1N1) pdm09 virus in Hebei, 2017–2020[J]. Disease Surveillance, 2021, 36(10): 1081-1085. DOI: 10.3784/jbjc.202103240155

Drug resistance of influenza A (H1N1) pdm09 virus in Hebei, 2017–2020

  •   Objective  To analyze the resistance of influenza A (H1N1) pdm09 virus to neuraminidase inhibitors (NAIs) in Hebei province during 2017–2020 and provide evidence for the prevention and control of influenza.
      Methods  A total of 37 strains of influenza A (H1N1) pdm09 virus isolated in Hebei during 2017–2020 were selected for oseltamivir and zanamivi resistance tests with fluorescence radiation assay. A total of 38 strains of influenza A (H1N1) pdm09 virus were selected for neuraminidase (NA) sequencing analysis.
      Results  The median of half maximal inhibitory concentration (IC50) of oseltamivir to strain A/Hebeixinhua/SWL1106/2017 was 30.98 nmol/L. To 36 virus strains, the average IC50 of oseltamivir was of 0.46 nmol/L (ranged 0.07–1.14 nmol/L) while the average IC50 of zanamivi was 0.27 nmol/L (ranged 0.07–0.85 nmol/L). Sequence analysis showed that 1 strain had H275Y mutation in amino acid of the NA gene, suggesting that the strain was oseltamivir resistant.
      Conclusion  The majority of influenza A (H1N1) pdm09 virus strains isolated in Hebei during 2017–2020 were sensitive to NAIs.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return